The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 193.9% in November

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,240,000 shares, a growth of 193.9% from the November 15th total of 421,900 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.4% of the company’s stock are short sold.

Oncology Institute Stock Down 3.1 %

Shares of NASDAQ TOI traded down $0.01 during mid-day trading on Friday, reaching $0.22. 247,852 shares of the company’s stock traded hands, compared to its average volume of 534,100. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.50. The stock has a market cap of $16.84 million, a P/E ratio of -0.29 and a beta of 0.43. The business has a 50-day simple moving average of $0.26 and a 200 day simple moving average of $0.36.

Insiders Place Their Bets

In other news, Director Brad Hively bought 250,000 shares of the stock in a transaction dated Tuesday, November 26th. The shares were bought at an average cost of $0.17 per share, with a total value of $42,500.00. Following the completion of the transaction, the director now directly owns 616,753 shares of the company’s stock, valued at $104,848.01. This trade represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds have recently added to or reduced their stakes in the stock. HighTower Advisors LLC raised its stake in shares of Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after purchasing an additional 53,382 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Oncology Institute by 142.3% during the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock worth $156,000 after buying an additional 199,300 shares in the last quarter. Finally, Tiff Advisory Services LLC raised its position in Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after buying an additional 995,280 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.